Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ARCTNASDAQ:EPIXNASDAQ:EPZMNASDAQ:GTHXNYSEAMERICAN:ZOM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$26.98-3.4%$34.18$17.52▼$43.81$726.30M2.6453,759 shs266,354 shsEPIXESSA Pharma$6.25-2.3%$8.39$2.56▼$11.67$283.14M1.62136,534 shs41,308 shsEPZMEpizyme$1.47$1.47$0.41▼$5.80$247.44M-0.413.23 million shs7,960 shsGTHXG1 Therapeutics$3.99-4.8%$3.69$1.08▼$5.00$208.40M1.731.30 million shs343,795 shsZOMZomedica$0.13$0.00$0.12▼$0.25$127.59M15.21 million shs2.53 million shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+3.22%-7.30%-17.61%-13.26%-2.00%EPIXESSA Pharma0.00%-13.86%-29.13%-27.19%+136.16%EPZMEpizyme0.00%0.00%0.00%0.00%0.00%GTHXG1 Therapeutics+2.20%+2.70%+4.75%+13.86%+57.52%ZOMZomedica0.00%0.00%+1.67%+4.23%-33.73%The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics1.7172 of 5 stars3.50.00.00.02.13.30.6EPIXESSA Pharma1.9806 of 5 stars3.54.00.00.00.03.30.0EPZMEpizymeN/AN/AN/AN/AN/AN/AN/AN/AGTHXG1 Therapeutics3.5802 of 5 stars3.32.00.03.82.90.80.6ZOMZomedicaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics3.00Buy$61.33127.33% UpsideEPIXESSA Pharma3.00Buy$16.50164.00% UpsideEPZMEpizymeN/AN/AN/AN/AGTHXG1 Therapeutics2.50Moderate Buy$9.33133.92% UpsideZOMZomedicaN/AN/AN/AN/ACurrent Analyst RatingsLatest EPZM, ZOM, EPIX, ARCT, and GTHX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.003/20/2024ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.003/8/2024ARCTArcturus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/28/2024GTHXG1 TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00 ➝ $5.002/28/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.002/13/2024GTHXG1 TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$5.00 ➝ $4.002/13/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.002/8/2024ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $48.001/24/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$169.93M4.27N/AN/A$10.42 per share2.59EPIXESSA PharmaN/AN/AN/AN/A$3.30 per shareN/AEPZMEpizyme$37.43M6.61N/AN/A($0.54) per share-2.72GTHXG1 Therapeutics$82.51M2.53N/AN/A$0.68 per share5.87ZOMZomedica$25.19M5.07N/AN/A$0.24 per share0.54Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$29.73M-$1.04N/A10.22N/A-15.65%-18.22%-11.95%5/14/2024 (Estimated)EPIXESSA Pharma-$26.58M-$0.59N/AN/AN/AN/A-17.41%-17.04%5/14/2024 (Estimated)EPZMEpizyme-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/AGTHXG1 Therapeutics-$47.97M-$0.95N/AN/AN/A-58.13%-106.04%-33.99%5/1/2024 (Confirmed)ZOMZomedica-$34.53M-$0.04N/A∞N/A-137.10%-8.13%-7.68%5/9/2024 (Estimated)Latest EPZM, ZOM, EPIX, ARCT, and GTHX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2024N/AGTHXG1 Therapeutics-$0.19N/A+$0.19N/AN/AN/A 4/1/2024Q4 2023ZOMZomedicaN/A-$0.01-$0.01N/A$7.00 million$7.34 million 3/7/2024Q4 2023ARCTArcturus Therapeutics-$1.69-$0.32+$1.37-$0.32$64.14 million$33.99 million2/28/202412/31/2023GTHXG1 Therapeutics-$0.27-$0.21+$0.06-$0.21$12.83 million$14.87 million 2/13/202412/31/2023EPIXESSA Pharma-$0.17-$0.14+$0.03-$0.14N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/AEPZMEpizymeN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/AZOMZomedicaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A4.724.72EPIXESSA PharmaN/A40.7440.74EPZMEpizymeN/A5.355.19GTHXG1 Therapeutics1.463.873.45ZOMZomedicaN/A11.0610.49OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%EPIXESSA Pharma75.12%EPZMEpizyme76.45%GTHXG1 Therapeutics24.21%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics13.80%EPIXESSA Pharma14.70%EPZMEpizyme23.40%GTHXG1 Therapeutics8.23%ZOMZomedica4.18%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18026.92 million23.20 millionOptionableEPIXESSA Pharma5044.24 million37.74 millionOptionableEPZMEpizyme250168.33 million128.97 millionOptionableGTHXG1 Therapeutics10052.23 million47.94 millionOptionableZOMZomedica144979.95 million938.99 millionNot OptionableEPZM, ZOM, EPIX, ARCT, and GTHX HeadlinesSourceHeadlineWhat’s Happening at the Defender Kentucky Three Day Eventeventingnation.com - April 21 at 12:53 PMZomedica (NYSEAMERICAN:ZOM) Stock Price Down 4.3%americanbankingnews.com - April 21 at 6:12 AMZomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024accesswire.com - April 9 at 6:30 AMZomedica Corp. (AMEX:ZOM) Q4 2023 Earnings Call Transcriptmsn.com - April 2 at 4:06 PMQ4 2023 Zomedica Corp Earnings Callfinance.yahoo.com - April 2 at 8:30 AMZOM Stock Earnings: Zomedica Beats Revenue for Q4 2023investorplace.com - April 1 at 9:06 PMZomedica reports Q4 resultsmsn.com - April 1 at 5:27 PMZomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidityaccesswire.com - April 1 at 4:05 PMThe Next Millionaire-Makers: 3 Penny Stocks With Massive Upside Potentialinvestorplace.com - April 1 at 3:12 PMZomedica to Report Fourth Quarter and Full Year 20…pharmiweb.com - March 20 at 9:17 AMZomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ETaccesswire.com - March 20 at 6:30 AMZomedica Pharmaceuticals Corp (ZOM)investing.com - March 15 at 7:52 AMZomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platformaccesswire.com - March 14 at 6:30 AMZomedica Provides NYSE American Listing Updateaccesswire.com - March 13 at 4:45 PMSidoti & Company, LLC: Sidoti Events, LLC's Virtual March Small-Cap Conferencefinanznachrichten.de - March 12 at 11:26 AMZomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferencesfinanznachrichten.de - March 12 at 8:22 AMZomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferencesaccesswire.com - March 12 at 6:30 AMZomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogsaccesswire.com - March 7 at 6:30 AMZomedica to Present at the Sidoti Small Cap Conference March 14, 2024accesswire.com - March 5 at 6:30 AMZomedica Pharmaceuticals Corp. (ZOM)uk.finance.yahoo.com - March 1 at 2:46 PMZomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferencesfinanznachrichten.de - February 8 at 9:14 AMZomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferencesfinance.yahoo.com - February 8 at 9:14 AMZomedica Corp.: Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidationfinanznachrichten.de - February 6 at 5:00 PMLeading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)finance.yahoo.com - February 6 at 5:00 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsArcturus TherapeuticsNASDAQ:ARCTArcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.ESSA PharmaNASDAQ:EPIXESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.EpizymeNASDAQ:EPZMEpizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.G1 TherapeuticsNASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.ZomedicaNYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.